Learning Objectives:

1. Audience will know prevalence of various HER2 alterations in gyn malignancies and refer to trials appropriately

2. Audience will be able to describe result of TILS trails in cervical cancer.

3.  Audience will be able to interpret hormone receptor expression in endometrial cancer 

Session date: 
Monday, February 15, 2021 - 12:00pm to 1:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Gini F. Fleming, MD